In this monthly roundup, mergers, acquisitions and strategic investments continued to reshape the global beauty and retail landscape. From premium beauty brands and luxury fashion labels to wellness supplements and specialist cosmetics, companies are using acquisitions, divestments and venture capital investments to strengthen portfolios, expand into new categories and unlock future growth. At the same time, several high-profile transactions illustrate the increasingly selective nature of today’s dealmaking environment.
Portfolio optimisation remains a key priority for many beauty groups. KMI Brands completed the sale of NOUGHTY to Komerz, reflecting the continued appetite for established hair care brands with strong consumer recognition. Meanwhile, Waldencast agreed to sell Obagi Medical to Bridgepoint in a deal worth up to US$460 million, allowing the company to sharpen its strategic focus while giving the premium clinical skincare brand a new platform for international expansion.
Luxury assets also remain in demand. LVMH agreed to sell Marc Jacobs to WHP Global, highlighting the continued reshaping of luxury brand portfolios as groups focus investment on their highest-growth assets. In prestige beauty retail, CK Hutchison is reportedly exploring the sale of Marionnaud to BEHN, a move that could further consolidate Europe’s premium beauty retail market.
Strategic acquisitions continue to support category expansion. Unilever agreed to acquire US greens supplement brand Grüns, reinforcing its growing commitment to health, wellness and beauty-from-within categories. As consumer interest in holistic wellbeing continues to rise, nutrition and personal care are becoming increasingly interconnected investment priorities.
In China, Proya strengthened its colour cosmetics business by taking a controlling stake in Flower Knows, demonstrating continued confidence in premium makeup brands with strong digital engagement and younger consumer appeal. The transaction reflects the ongoing consolidation of China’s fast-evolving beauty market as domestic leaders seek to broaden their product portfolios.
Venture capital activity also remains strong in beauty biotechnology. OliX Pharmaceuticals secured KRW110 billion in investment from L’Oréal’s venture fund alongside Weiss Asset Management, highlighting continued investor confidence in next-generation life sciences and advanced skincare technologies. Strategic investment in biotechnology is becoming an increasingly important route for major beauty companies seeking access to breakthrough innovation.
Beyond beauty, retail consolidation remains active. JD.com is reportedly exploring a potential £2 billion acquisition of UK retailer The Very Group, illustrating continued interest from international companies seeking to expand their presence in major consumer markets through established retail platforms.
Not every reported transaction, however, results in a deal. Coty and Interparfums both denied speculation surrounding discussions over the Boss and Burberry fragrance licences, serving as a reminder that licensing agreements remain among the beauty industry’s most strategically sensitive assets and frequently attract market speculation.
Taken together, this monthly roundup highlights a dealmaking environment focused on quality over quantity. Companies are investing selectively in premium brands, wellness, biotechnology and strategic retail assets while streamlining portfolios to concentrate resources on long-term growth opportunities. In 2026, successful dealmakers are not simply acquiring scale—they are building stronger, more focused businesses positioned for the next generation of beauty consumers.
